Compared to our previous single-compartment and multi-compartment results in the absence of sVEGFR1 [59], [59], the addition of sVEGFR1 into the VEGF system did not significantly alter the predicted total VEGF distribution in normal muscle tissue.
However, by predicting the dynamics of the synapse boundary directly on the cell scale, the present model allows direct comparison with the experiments that were suggested by the previous fixed-compartment model [5].
The control values for all binding and coupling kinetic rates (Table 3), except for the new interactions involving sVEGFR1, were kept identical to those from our previous single-compartment skeletal muscle model [54].
For this tissue, we use parameters reported in a previous one-compartment model [ 4].
We constructed a compartment model of VEGF transport and interactions with cell receptors representing the whole human body that is an extension of previous one-compartment models for breast tumor tissue [ 4] and skeletal muscle [ 6].
In previous studies using compartment models, compartments were devised using a least squares fit to the spray zone residence time per pass (the time particles spend in the spray during a single pass through the spray zone) and the cycle time (the time between successive visits to the spray zone) distributions.
Unlike the previous (successful treatment) compartment, diagnostic delay is not explicitly incorporated into this compartment, as to do so would prolong the duration of time until individuals who default re-enter the 'late active' compartment.
These data corroborate previous reports where compartment-specific expression in the midgut was studied using enhancer-trap analysis (Murakami et al. 1994; Marianes and Spradling 2013), but the transcription factors that coordinate differential expression in the midgut are unknown.
The remainder have previous assignments to other compartments.
In agreement with most previous reports, a two compartment disposition model was selected for lumefantrine, whereas a one compartment model was adequate for desbutyl-lumefantrine [ 49– 51].
